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Summary
Patients	with	haematological	malignancies	are	at	risk	for	invasive	fungal	diseases	(IFD).	A	survey	
was	conducted	in	all	Dutch	academic	haematology	centres	on	their	current	diagnostic,	prophy-
lactic	and	therapeutic	approach	towards	IFD	in	the	context	of	azole-resistance.	In	all	8	centres,	a	
haematologist	and	microbiologist	filled	in	the	questionnaire	that	focused	on	different	subgroups	
of	haematology	patients.	Fungal	prophylaxis	during	neutropaenia	was	directed	against	Candida 
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1  | INTRODUC TION
Invasive	fungal	disease	(IFD)	occur	in	5%-	40%	of	patients	with	hae-
matological	malignancies.	Approximately	95%	of	the	IFD	are	caused	
by Aspergillus and Candida	species.1	IFD	is	associated	with	a	very	sig-
nificant	morbidity	and	mortality	that	is	explained	by	the	difficulties	
in	diagnosing	IFD	rapidly.1	In	addition,	the	presence	of	an	IFD	leads	
to	a	delay	 in	subsequent	anti-	leukemic	therapy,	and	therefore	also	
indirectly	affects	the	outcome	of	the	patient.2
Antifungal	 prophylaxis	 prevent	 IFD	 during	 acute	 myeloid	 leu-
kaemia	(AML)	therapy	or	during	graft-	versus-	host	disease	(GVHD).	
These	benefits	have	to	be	weighed	against	risks	of	drug	toxicity,	in-
teractions,	selection	of	resistance	and	costs.	Different	opinions	on	
the	preferred	antifungal	strategy	in	these	patients	exist	and	the	ap-
proach	varies	considerably	from	institution	to	institution.
Over	the	last	10	years	resistance	of	A. fumigatus	against	triazoles,	
has	become	a	significant	problem	in	the	Netherlands	but	has	recently	
also	been	reported	in	other	countries.3-5	Triazole-	resistance	can	de-
velop	through	long-	term	azole	therapy	in	patients	with	chronic	pul-
monary	aspergillosis.	However,	the	selection	of	tri-	azole	resistance	in	
the	environment	by	the	use	of	azole	fungicides	is	far	more	important.	
This	in	agreement	with	the	observation	that	the	majority	of	triazole-	
resistant	A. fumigatus	 strains	contain	 the	environmental	TR34/L98H	
or	the	TR46/Y121F/T289A	mutation	pattern	 in	their	Cyp51A	gene.
6 
This	gene	encodes	for	the	target	enzyme	of	triazoles.7	Infections	with	
a	triazole-	resistant	A. fumigatus	result	in	a	high	mortality	and	the	best	
diagnostic	and	treatment	approach	is	uncertain.5,8	We	conducted	a	
survey	on	fungal	diagnostics,	antifungal	prophylaxis	and	treatment	in	
all	Dutch	academic	haematology	centres.	The	survey	facilitated	the	
development	of	a	consensus	approach	towards	the	management	of	
invasive	aspergillosis	(IA)	in	a	context	of	rising	azole-resistance.
2  | MATERIAL S AND METHODS
A	 questionnaire	 was	 sent	 to	 a	 haematologist	 and	 a	 microbiolo-
gist	with	special	interest	in	supportive	care	and	medical	mycology	
respectively	and	both	parties	were	asked	to	answer	as	a	team	for	
their	centre.	The	questionnaire	focused	on	(i)	primary	prophylaxis	
during	AML	chemotherapy,	during	allogeneic	hematopoietic	stem	
cell	transplantation	(allo-	HSCT)	and	at	the	time	of	GVHD.	(ii)	How	
was	screened	for	IFD	and	which	diagnostic	tests	were	performed.	
(iii)	The	current	antifungal	treatment	for	different	clinical	scenar-
ios.	The	results	were	processed	and	during	a	consensus	meeting	
the	protocol	 for	The	Azole-Resistance	MANagement	 (AzoRMan)	
Study	was	developed	and	implemented.
3  | RESULTS
3.1 | Prophylaxis
3.1.1 | Prophylaxis directed against Candida
Fluconazole	is	given	during	neutropaenia	of	>10	days	in	4/8	centres	
at	very	different	dosages	and	amphotericin	B	oral	suspension	was	
used	in	2	(Table	1).	One	centre	also	uses	amphotericin	B	lozenge.	
One	 centre	 starts	 fluconazole	 when	 surveillance	 cultures	 grow	
Candida.	 If	 surveillance	 cultures	 show	 Candida	 species	 resistant	
to	fluconazole,	some	centres	switch	to	amphotericin	B	suspension	
and	 one	 centre	 adds	 amphotericin	 B	 suspension	 to	 fluconazole.	
Finally,	one	centre	 stops	 fluconazole	and	no	other	prophylaxis	 is	
initiated.
3.1.2 | Mould- active prophylaxis
Only	 one	 centre	 applies	 mould-	active	 prophylaxis	 (itraconazole)	
during	chemotherapy	induced	neutropaenia	of	>10	days	and	during	
myeloablative	allo-	HSCT.	Therapeutic	drug	monitoring	of	itracona-
zole	is	performed	and	when	no	effective	plasma	concentrations	are	
reached,	a	switch	to	voriconazole	is	made.	In	another	centre	nebu-
lised	liposomal	amphotericin	B	(L-	AmB)	at	15	mg	QD,	twice	weekly	
is	used	for	this	purpose.	All	centres	start	mould-	active	prophylaxis	
when	corticosteroids	are	given	 for	GVHD	but	 the	drugs	of	choice	
differ	(Table	1).
and	 consisted	of	 fluconazole	 and/or	 amphotericin	B	 suspension.	Mould-	active	prophylaxis	was	
given	 to	 acute	myeloid	 leukaemia	 patients	 during	 chemotherapy	 in	 2	 of	 8	 centres.	 All	 centres	
used	azole	prophylaxis	in	a	subset	of	patients	with	graft-	versus-	host	disease.	A	uniform	approach	
towards	the	diagnosis	and	treatment	of	IFD	and	in	particular	azole-	resistant	Aspergillus fumigatus 
was	lacking.	In	2017,	all	centres	agreed	to	implement	a	uniform	diagnostic	and	treatment	algorithm	
regarding	invasive	aspergillosis	with	a	central	role	for	comprehensive	diagnostics	and	PCR-	based	
detection	of	azole-resistance.	This	study	(DB-	MSG	002)	will	re-	evaluate	this	algorithm	when	280	
patients	have	been	treated.	A	heterogeneous	approach	towards	antifungal	prophylaxis,	diagno-
sis	 and	 treatment	was	 apparent	 in	 the	Netherlands.	 Facing	 triazole-	resistance,	 consensus	was	
reached	on	the	implementation	of	a	uniform	diagnostic	approach	in	all	8	centres.
K E Y W O R D S
azole-resistance,	IFD,	invasive	aspergillosis,	management
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3.2 | Diagnosis
3.2.1 | Diagnostic procedures
A	chest	CT	 is	routinely	performed	in	all	centres	after	3	to	5	days	of	
neutropenic	fever	without	an	infectious	focus	despite	antibiotic	ther-
apy	(Table	2).	When	the	chest	CT	scan	shows	pulmonary	infiltrates	a	
broncho-	alveolar	lavage	(BAL)	with	galactomannan	(GM)	detection	and	
fungal	culture	 is	performed	in	all	centres	 (if	clinically	feasible).	Twice	
weekly	serum	GM	monitoring	as	a	screening	tool	is	performed	in	one	
centre	only.	Two	centres	perform	an	Aspergillus	DNA	PCR	on	BAL	rou-
tinely;	in	one	centre	this	is	done	only	when	BAL	GM	is	positive	or	when	
an	EORTC	compatible	radiological	finding	is	suggestive	of	an	IFD.
3.2.2 | Susceptibility testing
Different	 Aspergillus	 susceptibility	 testing	 methods	 are	 used:	
VIPcheck™	 or	 Etest	 followed	 by	 confirmation	 with	 testing	 ac-
cording	to	the	European	Committee	on	Antibiotic	Susceptibility	
Testing	 (EUCAST)	method	when	 resistance	 is	 suspected	based	
on	 the	 screening	 assay	 (Table	3).	 The	 EUCAST	 method	 is	 op-
erational	 in	 the	 mycology	 reference	 laboratory	 (RefLab).	
Resistance	 screening	 is	 done	 in	 all	 but	 one	 centre	 with	 a	 4-	
well	plate	 (VIPcheck™)	 in	which	three	of	the	four	wells	contain	
agar	 supplemented	 with	 an	 azole	 (voriconazole,	 itraconazole	
and	 posaconazole)	 and	 the	 fourth	 functions	 as	 a	 growth	 con-
trol.	The	other	centre	uses	the	Etest	(bioMérieux)	for	resistance	
TABLE  1 Prophylactic	strategies	used	against	Candida	and	Aspergillus
Antifungal agent Dosage Number of centres
Candida	prophylaxis	during	longstanding	
chemotherapy-	induced	neutropaenia
Fluconazole 50	mg/24	h 1
200	mg/24	h 2
400	mg/24	h 1
Amphotericin	B	suspension 500	mg/6	h 2
200	mg/12	h 1
Fluconazole	when	surveillance	
cultures	grow	Candida
1
Anti-	mould	prophylaxis	in	AML/MDS/AlloTx	
during	longstanding	chemotherapy-	induced	
neutropaenia
Itraconazole	suspension Start	with	200	mg	bid,	dose	
increased	based	on	TDM	results
1
L-	AmB	aerosols 15	mg	twice	weekly 1
None 6
AlloTx	with	GVHD	treated	with	systemic	
corticosteroids
Itraconazole Start	with	200	mg	bid,	dose	
increased	based	on	TDM	results
1
2,5	mg/kg/12	h 1
Voriconazole 200	mg/12	h 1
Posaconazole 300	mg/24	h	tablets 5
AlloTx,	Allogeneic	stem	cell	 transplantation;	AML,	Acute	Myeloid	Leukaemia;	GVHD,	Graft-	versus-	Host	disease;	MDS,	Myelodysplastic	syndrome;	
TDM,	Therapeutic	Drug	Monitoring.	L-	AmB,	liposomal	amphotericin-	B.
Diagnostic procedure Possibilities Nr of centres
Screening	with	serum	GM	(twice	weekly)	
during	prolonged	neutropaenia
Yes 1
No 7
Chest	CT-	scan	when	3-	5	days	neutropaenic	
FUO	despite	broad-	spectrum	antibiotic	
treatment
Yes 8
No 0
Bronchoscopy	with	BAL	(when	no	evident	
cause	for	infiltrative	lesions	on	imaging)
Yes 8
No 0
GM	measurement	on	BAL	fluid	sample,	if	BAL	
sampling	is	performed
Yes 8
No 0
Aspergillus	species	PCR	on	BAL	fluid Yes,	always 2
Yes,	if	GM	is	positive 1
No 5
BAL,	Bronchoalveolar	 lavage;	GM,	Galactomannan;	 FUO,	Fever	of	 unknown	origin;	 IFD,	 Invasive	
Fungal	Diseases.
TABLE  2 Diagnostic	strategies	used	in	
patients	at	risk	for	or	suspected	of	having	
an	IFD
4  |     SCHAUWVLIEGHE Et AL.
screening.	 Simultaneous	 to	 the	 screening	 test,	 4	 centres	 send	
the	Aspergillus	strain	directly	to	the	RefLab	for	MIC	testing.	PCR	
testing	 for	 the	 presence	of	 TR34	 and	TR46	 directly	 on	 cultured	
A. fumigatus	colonies	is	performed	on-	site	in	4	centres	to	speed	
up	 resistance	 detection.	 A	 PCR-	based	 resistance	 assay	 is	 per-
formed	directly	on	BAL	in	3	centres.	For	this	purpose,	a	commer-
cially	available	qPCR	(AsperGenius®)	or	an	in-	house	PCR	is	used.	
One	centre	sends	BAL	samples	to	the	RefLab	for	PCR	testing.
3.3 | Treatment
Suspected invasive fungal infection:
All	centres	use	voriconazole	as	the	initial	treatment	for	patients	in	a	
respiratory	stable	condition	suspected	of	having	an	IFD	while	wait-
ing	 for	 the	 microbiological	 tests	 (Table	4).	 One	 centre	 frequently	
uses	 posaconazole	 as	 well	 and	 another	 centre	 with	 a	 high	 local	
azole-resistance	prevalence	prefers	L-	AmB	if	the	patient	is	very	ill.	
The	feasibility	of	BAL	fluid	sampling	is	the	decisive	factor	in	another	
centre	to	guide	therapy	and	voriconazole	is	given	if	a	BAL	is	obtained	
and	 therefore,	 the	 detection	 of	 azole-resistance	 becomes	 more	
likely.	If	BAL	is	not	feasible,	this	centre	gives	L-	AmB	as	antifungal.
Proven or probable IA
Voriconazole	 is	 the	 treatment	 of	 choice	 for	 all	 centres	 when	 a	
BAL-	GM	assay	is	positive	in	a	respiratory	stable	patient	and	the	le-
sions	on	chest	CT	are	not	widespread,	fungal	culture	remains	neg-
ative	 and	 no	 susceptibility	 PCR	 is	 performed	 or	 the	 test	was	 not	
successful.	In	the	same	clinical	situation	with	a	patient	in	respiratory	
distress	or	with	extensive	pulmonary	infiltrates,	five	centres	would	
still	start	voriconazole.	Two	centres	would	start	L-	AmB	and	one	cen-
tre	posaconazole.
Proven or probable IA and documented voriconazole 
resistance
If	voriconazole	resistance	 is	demonstrated	with	one	of	the	pheno-
typic	 susceptibility	 tests	 or	 by	 a	 resistance	 PCR,	 all	 centres	 give	
L-	AmB.
3.4 | Therapeutic drug monitoring
3.4.1 | Voriconazole
Two	 centres	 do	 not	 perform	 therapeutic	 drug	 monitoring	 (TDM).	
Two	centres	do	TDM	when	toxicity	or	treatment	failure	is	suspected.	
The	other	centres	routinely	perform	TDM.
3.4.2 | Posaconazole
Three	 centres	 always	 perform	TDM	and	 two	 centres	 do	 not.	 The	
other	three	centres	perform	TDM	on	indication	only.
3.5 | Triazole resistance data
In	2016,	A. fumigatus	isolates	from	784	clinical	patients	were	screened	
for	triazole	resistance	using	a	4-	well	agar	plate	(VIPcheck™).	Isolates	
that	grew	on	the	triazole-	containing	agar	have	a	high	probability	of	
resistance	and	were	sent	to	the	Reflab	for	phenotypic	and	genotypic	
characterisation.	101	 isolates	 (12.9%)	were	 triazole-	resistant,	which	
TABLE  3 Diagnostic	tests	done	on	BAL	fluid	samples
Susceptibility assay Possibilities Nr of centres
Aspergillus species:	Screening	for	azole-resistance	
with	VIP™check-	testing
Yes 7
No 1 
Sends	Aspergillus	strain	directly	to	RefLab
Phenotypic	azole-resistance	testing	(EUCAST)	of	
cultured	Aspergillus	strains
Directly	sent	to	RefLab	for	EUCAST	
testing
4
Send	to	RefLab	only	if	VIP™	screening	is	
positive
2
Send	to	RefLab	only	if	E-	test	is	positive 1
EUCAST	testing	on	site=RefLab 1
Testing	for	RAM	on	cultured	Aspergillus	strains Yes,	in-	house 4
Yes,	not	in-	house 1
No 3
Testing	for	RAM	(CYP51A)	directly	on	BAL	fluid Yes 2
No 4
On	indication	(if	BAL	culture	is	negative	
and	patient	is	not	doing	clinically	well)
1
Sends	BAL	sample	to	the	RefLab 1
EUCAST,	The	European	Committee	on	Antimicrobial	Susceptibility	Testing;	GM,	Galactomannan;	VIP™	testing,	resistance	assay	(explanation:	see	text);	
RAM,	Resistance	associated	mutations	(TR34/L98H,	TR53,	and	TR46/Y121F/T289A);	RefLab,	National	mycology	reference	laboratory	in	Nijmegen	(The	
Netherlands);	BAL,	Broncho-	alveolar	lavage.
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was	higher	than	2014	(7.2%)	and	2015	(10.7%).	In	individual	centres,	
resistance	ranged	from	9.5%	to	20.5%.6	Recently,	a	nationwide	Dutch	
cohort	study	reported	data	from	144	patients	with	influenza	pneumo-
nia	admitted	to	all	8	University	Intensive	Care	Units.	23	patients	(16%)	
were	diagnosed	with	 influenza-	associated	 invasive	aspergillosis	 and	
triazole	resistance	was	reported	in	29%	of	those	with	a	positive	A. fu-
migatus	culture.9	The	clinical	relevance	of	triazole	resistance	was	also	
described	in	another	recent	study	in	which	a	multiplex	real-	time	PCR	
test	(AsperGenius©	assay)	was	performed	on	BAL	samples	from	201	
patients.	This	qPCR	allows	the	simultaneous	detection	of	Aspergillus 
species	and	identification	of	the	most	common	mutations	in	the	A. fu-
migatus Cyp51A	conferring	resistance	by	using	melting	curve	analysis.	
In	11	of	the	68	patients	in	which	the	resistance	PCR	could	be	success-
fully	 performed,	 the	 TR34/L98H	 or	 TR46/T289A/Y121F	 resistance	
pattern	was	documented.	More	importantly,	the	detection	of	resist-
ance	correlated	with	voriconazole	treatment	failure.8
4  | DISCUSSION
4.1 | Prophylaxis directed at Candida
The	European	Conference	on	Infections	in	Leukaemia	(ECIL)	5	guide-
lines	 on	 antifungal	 prophylaxis	 recommends	 fluconazole	 (400	mg	
q24	h)	when	the	mould	infections	are	rare	and	a	mould-	directed	diag-
nostic	approach	is	in	place	(B-	I).10	The	latter	is	the	case	in	all	centres	
that	were	surveyed	but	the	dose	of	fluconazole	varies	among	cen-
tres	and	is	generally	lower	than	was	used	in	most	randomised	trials	
(400	mg	q24	h).11-15	Some	studies	suggest	that	lower	doses	may	suf-
fice.16	Three	centres	use	oral	amphotericin	B	as	primary	prophylaxis	
and	 in	others	oral	amphotericin	B	 is	given	on	top	of	 fluconazole	 if	
surveillance	 cultures	 remain	 positive.	 In	 a	 pooled	 analysis	 of	 oral	
fluconazole	vs	amphotericin	B	no	significant	advantage	of	either	of	
the	two	drugs	was	observed.	Data	on	the	efficacy	of	prophylactic	
amphotericin	B	are	scarce.17	According	to	the	EBMT,	fluconazole	is	
the	drug	of	choice	for	the	prophylaxis	of	invasive	candidiasis	before	
engraftment	in	allo-	HSCT	recipients,	and	may	be	started	at	the	be-
ginning	or	after	the	end	of	the	conditioning	regimen	(A-	I).18
4.2 | Mould- active prophylaxis
The	advantage	of	primary	mould-	active	prophylaxis	with	posacon-
azole	was	shown	 in	two	randomised	trials.13,14	The	Dutch	guide-
line	 on	 antifungal	 management	 as	 well	 as	 the	 ECIL-	5	 guideline	
recommends	posaconazole	for	primary	prophylaxis	(A-	I)	when	the	
incidence	of	mould	infections	is	high.10,19	Firm	criteria	for	what	con-
stitutes	`high	risk`	are	lacking	but	it	has	been	proposed	that	sub-
populations	with	>8%-	10%	fall	 into	 this	category.	Unfortunately,	
reliable	data	on	the	local	prevalence	of	mould	infections	are	often	
lacking.20	One	centre	administers	aerosolised	L-	AmB	twice	weekly	
for	 the	 prevention	 of	 IFD	 in	AML	 patients	 undergoing	 intensive	
chemotherapy.	Its	efficacy	and	cost-	effectiveness	have	been	dem-
onstrated	 in	 a	 single-	centre	 randomised	 placebo-	controlled	 trial	
and	an	observational	study.21,22	One	centre	uses	 itraconazole	as	
antifungal	prophylaxis.	A	major	concern	of	itraconazole	is	its	poor	
gastrointestinal	tolerance	and	CYP3A4	inhibitory	properties.	Both	
the	ECIL-	5	and	the	 IDSA	guidelines	give	moderate	recommenda-
tions	against	its	use.10,23	All	centres	use	a	diagnostic	protocol	that	
includes	a	lung	CT	after	three	to	5	days	of	fever	despite	antibiotic	
TABLE  4 Treatment	of	invasive	aspergillosis
Presentation Clinical condition Treatment options Nr of centres
Chest	CT:	suspected	IFD	but	microbiological	
results	pending
Respiratory	and	clinically	stable Voriconazole 8
Respiratory	and	clinically	instable Voriconazole 6
L-	AmB 1
+BAL	possible Voriconazole 1
+BAL	impossible L-	AmB
BAL	GM	pos,	Culture/PCR	neg Respiratory	and	clinically	stable Voriconazole 8
Critically	ill Voriconazole 5
L-	AmB 2
Posaconazole 1
Resistance	detected	by	culture	or	PCR Respiratory	and	clinically	stable/instable L-	AmB 8
TDM	voriconazole No 2
Sometimes* 2
Always 4
TDM	posaconazole No 2
Sometimes* 3
Always 3
BAL,	Bronchoalveolar	lavage;	Resp,	Respiratory;	L-	AmB,	liposomal	amphotericin-	B;	IFD,	Invasive	Fungal	Diseases;	PCR,	Polymerase	Chain	Reaction;	
GM,	Galactomannan;	TDM,	Therapeutic	Drug	Monitoring;	+BAL	possible/impossible:	BAL	sampling	was	possible/impossible;	*Sometimes,	when	toxic-
ity	or	therapeutic	failure	is	suspected.
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therapy	and	proceed	to	BAL	sampling	when	 infiltrates	are	docu-
mented.	Indeed,	a	survival	benefit	of	azole	prophylaxis	compared	
with	 a	 diagnostic-	driven	 approach	 has	 not	 been	 convincingly	
shown	and	so	both	continue	to	be	reasonable	strategies.
4.3 | Mould- active prophylaxis in GVHD
Antifungal	 prophylaxis	 has	 been	 established	 as	 standard	 of	 care	
after	allo-	HSCT	with	grade	II	or	higher	GVHD,	but	issues	concern-
ing	drug-	drug	interactions	and	factors	compromising	bioavailability	
have	to	be	considered.	Ullman	et	al.	performed	a	randomised	trial	in	
which	fluconazole	and	posaconazole	oral	solution	were	compared	as	
fungal	prophylaxis	in	patients	with	GVHD.	Posaconazole	prevented	
IA	and	resulted	in	lower	numbers	of	deaths	related	to	IFD	although	
the	 overall	 mortality	 did	 not	 differ.14	 All	 centres	 administer	 azole	
prophylaxis	 (4	posaconazole,	2	voriconazole,	2	 itraconazole)	to	pa-
tients	with	GVHD	of	grade	 II	 or	higher	 in	 accordance	with	ECIL-	5	
recommendations	in	which	an	A-	I	recommendation	is	given	for	posa-
conazole	and	a	B-	I	to	itraconazole	and	voriconazole.10
4.4 | Diagnosis of IA
Pulmonary	 imaging	with	high-	resolution	CT	 (HRCT)	was	 shown	 to	
accelerate	and	improve	the	diagnosis	of	IA.23	The	IDSA	guideline	ad-
vocates	imaging	with	chest	CT	when	a	patient	is	suspected	to	have	
IA.	 IDSA	 guidelines	 also	 encourage	BAL	 since	 signs,	 symptoms	 or	
imaging	by	itself	are	often	aspecific.	All	centres	use	HRCT	and	BAL	
as	the	standard	diagnostic	procedure.	Serum	GM	monitoring	has	a	
moderate	sensitivity	of	±70%	but	is	 insensitive	in	non-	neutropenic	
patients	 and	 the	 specificity	 has	 varied	 between	 studies.23,24 Only 
one	centre	routinely	monitors	serum	GM	in	patients	with	prolonged	
neutropaenia.	 All	 centres	 measure	 BAL-	GM	 and	 Aspergillus	 DNA	
PCR	is	performed	in	3	centres	on	BAL	fluid	samples).	The	clinical	im-
plementation	of	PCR-	based	diagnosis	was	debated,	though	not	rec-
ommended	for	routine	clinical	practice	in	the	2016	IDSA	guidelines	
as	few	assays	have	been	standardised	and	well	validated.23
4.5 | Susceptibility testing
Azole-resistance	was	rare	in	The	Netherlands	before	the	year	2000	
but	its	prevalence	has	continued	to	increase	since	then.25	It	 is	cur-
rently	based	on	a	limited	number	of	resistance-	associated	mutations	
(RAMs)	 in	 the	 cyp51A-	gene	 (TR34/L98H,	 TR53,	 and	 TR46/Y121F/
T289A)	and	is	most	likely	caused	by	the	environmental	use	of	azole	
fungicides.7,26,27	The	TR34/L98H	and	TR46/Y121F/T289A	accounted	
for	83%	of	 resistance	mutations	 in	2016.6	 IDSA	guidelines	do	not	
recommend	standard	susceptibility	testing	but	these	guidelines	can-
not	be	applied	to	The	Netherlands.23,28	Case	series	indicate	that	IA	
caused	by	azole-	resistant	Aspergillus,	is	associated	with	a	very	high	
mortality.5,8	 The	 diagnostic	 tools	 used	 for	 the	 detection	 of	 azole-
resistance	 vary	 from	 centre	 to	 centre.	 Most	 perform	 agar-	based	
screening	 assays	 for	 resistance	 (VIPcheck™	 testing).	 Phenotypic	
azole-resistance	 testing	 according	 to	 the	 EUCAST	 method	 is	
performed	 by	 the	 National	 mycology	 reference	 laboratory	 only	
(RefLab).	Four	centres	directly	send	Aspergillus	strains	to	the	RefLab	
and	three	await	the	result	of	the	screening	assay.
Only	 very	 recently,	 the	 clinical	 validity	 and	 relevance	 of	 PCR-	
based	 susceptibility	 testing	 on	 BAL	 was	 demonstrated	 and	 may	
explain	 the	 limited	 uptake	 of	 resistance	 detection	 by	 PCR	 at	 the	
time	 of	 the	 survey.	 The	 AsperGenius®	 qPCR	 is	 a	 multiplex	 PCR	
and	 can	 detect	 the	 presence	 of	 Aspergillus	 DNA	 and	 in	 addition	
detect	 the	2	mutations	described	 above.8,29	 In	 a	 recent	 study	 the	
diagnostic	performance	was	evaluated	on	BAL-	samples	 in	201	pa-
tients.8,29	The	Aspergillus	BAL	qPCR,	had	a	sensitivity	of	89%	and	a	
specificity	of	89%	and	was	able	to	detect	A. fumigatus	that	carried	
resistance-	associated	mutations	 (RAM)	 in	 the	majority	of	patients,	
even	in	culture-	negative	BAL.	Furthermore,	this	study	showed	that	
response	to	voriconazole	therapy,	when	given	to	patients	 infected	
with	a	resistant	A. fumigatus	was	poor.8
4.6 | Treatment
The	ECIL-	6	guideline	attributes	an	A-	I	recommendation	to	both	vori-
conazole	and	isavuconazole	for	the	treatment	of	IA.30	Unfortunately,	
in	2016	surveillance	data	showed	that	triazole	resistance	was	pre-
sent	in	101	of	784	(12.9%)	patients	with	a	positive	A. fumigatus cul-
ture.6	 These	data	 are	based	on	 clinical	 isolates	 and	 it	 is	 uncertain	
what	fraction	of	these	patients	met	EORTC/MSG	criteria.	However,	
the	 clinical	 relevance	 of	 azole-resistance	 in	 patients	with	 an	 inva-
sive	Aspergillus	infection	was	described	in	a	recent	multicenter	study	
and	small	case	series	have	reported	a	very	high	mortality	in	patients	
infected	 with	 a	 voriconazole	 resistant	 A. fumigatus	 that	 received	
initial	 therapy	with	 voriconazole.5,8	 The	management	 of	 IA	 in	The	
Netherlands	in	the	context	of	a	progressively	rising	incidence	of	IA	
caused	by	azole-	resistant	A. fumigatus	strains	is	challenging	because	
evidence-	based	data	on	the	most	appropriate	management	of	 this	
emerging	clinical	problem	are	lacking.	At	the	time	of	the	survey,	all	
centres	start	voriconazole	when	the	patient	is	respiratory	and	clini-
cally	 stable	 while	 awaiting	 culture	 and/or	 resistance	 PCR	 results.	
In	a	clinically	unstable	patient,	 five	centres	still	 start	voriconazole,	
one	 centre	 starts	 posaconazole	 and	 another	 centre	 starts	 L-	AmB.	
The	feasibility	to	perform	a	BAL	(and	thus	cultures)	 is	the	decisive	
factor	for	one	centre.	In	2015	an	international	consensus	paper	on	
the	management	of	IA	caused	by	azole-	resistant	Aspergillus	isolates	
advised	L-	AmB	or	echinocandin-	voriconazole	combination	as	treat-
ment	 of	 choice	 in	 regions	 with	 environmental	 triazole	 resistance	
rates	of	Aspergillus	exceeding	10%.25
Therapeutic	drug	monitoring	was	systematically	used	in	four	cen-
tres	for	voriconazole,	on	indication	or	not	at	all	in	two	centres	each.	
Although	 some	 studies	 suggest	 a	 relation	 between	 voriconazole	
serum	levels	and	the	incidence	of	adverse	events,	randomised	clini-
cal	trials	that	convincingly	show	the	value	of	TDM	are	still	lacking.31
Off-	guideline	management	(as	compared	with	the	Dutch	guide-
line	on	fungal	infections)	was	observed	in	some	of	the	centres.19 One 
common	reason	for	a	delay	in	policy	change	after	new	convincing	ev-
idence	was	published	and	incorporated	in	guidelines	is	the	absence	
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of	a	dedicated	haematologist	with	special	interest	in	infectious	dis-
eases	and	supportive	haematological	care	who	critically	assesses	the	
local	practice	on	a	regular	basis.	We	asked	the	centres	for	the	rea-
sons	of	their	off-	guideline	policies	and	the	following	answers	were	
given:	The	continued	use	of	itraconazole	instead	of	posaconazole	as	
anti-	mould	prophylaxis	in	2	centres	was	driven	by	the	higher	costs	of	
other	azoles.	Both	centres	recently	moved	to	voriconazole	after	it	be-
came	available	as	a	generic	drug.	One	centre	preferred	voriconazole	
over	posaconazole	and	this	was	driven	by	the	unpredictable	absorp-
tion	of	the	oral	solution	and	the	lack	of	an	intravenous	formulation	
of	posaconazole	when	it	first	came	on	the	market.	Another	centre	
used	nebulised	liposomal	amphotericin-	B	as	anti-	mould	prophylaxis	
and	did	this	based	on	 locally	generated	evidence	that	supports	 its	
(cost-	)effectivity.21,22	Finally,	 the	continued	use	of	oral	 amphoteri-
cin-	B	solution	as	anti-	yeast	prophylaxis	(on	top	of	fluconazole)	was	
driven	by	the	fact	that	it	is	a	harmless	intervention	(as	no	systemic	
toxicity	occurs	with	a	non-	absorbed	drug)	and	because	with	this	pol-
icy,	the	incidence	of	candidaemia	had	been	very	low	with	this	policy	
for	more	than	15	years.	Therefore,	these	centres	were	reluctant	to	
change	a	safe	policy	that	seems	to	be	very	efficacious.
4.7 | Protocol
Following	 this	 survey,	 a	 consensus	 meeting	 was	 organised	 with	
representatives	 of	 all	 8	 centres	 and	 led	 to	 the	 development	 of	 a	
	standardised	diagnostic	and	therapeutic	protocol	on	the	management	
of	 IFD	 in	haematology	patients	 (Figure	1).	This	protocol	was	devel-
oped	 in	 collaboration	 with	 the	 recently	 established	 Dutch-	Belgian	
Mycosis	Study	Group	(DB-	MSG)	and	was	implemented	in	all	academic	
haematology	centres	in	2017	with	the	goal	to	gather	evidence	on	the	
F IGURE  1 Treatment	protocol	for	Azole-resistance	Management-	study.	MIC,	Minimal	Inhibitory	concentration;	IV,	Intravenously.	
*Posaconazole	HD	can	only	be	considered	as	treatment	option	when	the	MIC	(EUCAST)	≤1	g/dL.	HRCT,	High	Resolution	CT	scan;	PCR,	
polymerase	chain	reaction;	PO,	by	mouth;	BAL,	Broncho-	alveolar	lavage
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optimal	approach	towards	IFD	in	the	context	of	azole-resistance	(The	
Azole-Resistance	MANagement	 Study	 (AzoRMan)	 or	DB-	MSG	002	
study,	NCT03121235).	The	study	aims	to	demonstrate	that	the	use	
of	resistance	testing	by	PCR	on	BAL	fluid	from	haematology	patients	
with	suspected	IA	will	lead	to	an	improved	outcome	by	detecting	re-
sistance	earlier	and	changing	triazole	therapy	to	L-	AmB	as	soon	as	re-
sistance	is	detected.	Indeed,	the	majority	of	cases	of	IA	remain	culture	
negative	and	therefore,	the	use	of	resistance	testing	by	PCR	is	con-
sidered	crucial.8,32	The	AzoRMan-	study	 is	schematically	depicted	 in	
Figure	1	and	further	information	available	at	www.clinicaltrials.gov.	In	
brief,	treatment	is	based	on	the	documentation	of	azole	susceptibility	
or	resistance	and	step-	down	treatment	options	for	patients	treated	
for	documented	or	presumed	azole-resistance	are	given.
Treatment	with	 L-	AmB	 is	 advised	when	 azole-	resistance	 is	 doc-
umented	 or	when	 no	 susceptibility	 data	 are	 available	 and	 the	 local	
azole-	resistance	rate	 is	>10%.	This	 is	supported	by	the	fact	that	the	
A. fumigatus	strains	with	the	environmental	TR34/L98H	or	the	TR46/
Y121F/T289A	mutation	pattern	circulating	in	the	Netherlands	remain	
susceptible	to	L-	AmB.33	The	activity	of	L-	AmB	was	also	confirmed	in	
vivo	 in	 immunocompetent	 and	 immunosuppressive	 murine	 models	
of	 IA.34	This	approach	may	be	 less	appropriate	 in	different	 settings	
in	which	resistance	mechanisms	other	than	the	environmental	TR34/
L98H	or	the	TR46/Y121F/T289A	mutation	patterns	are	predominant.
35
If	a	treatment	response	is	observed	during	therapy	with	L-	AmB	
3	mg/kg/day,	a	switch	to	L-	AmB	5	mg/kg/day	three	times	a	week	or	
to	oral	posaconazole	(when	the	posaconazole	MIC	is	below	2	mg/L)	
is	made	with	a	posaconazole	target	trough	serum	level	of	3-	4	mg/L.	
The	 logical	 behind	 the	 posaconazole	 strategy	 is	 the	 observation	
that	Aspergillus	 strains	 carrying	 RAMs	 often	 have	 a	 posaconazole	
minimum	 inhibitory	 concentrations	 (MIC)	 that	 is	 <2	mg/L.36	 The	
efficacy	 of	 posaconazole	 at	 high	 serum	 levels	 was	 demonstrated	
in	 a	 pharmacodynamic	 study	 in	mice	with	 invasive	 azole-	resistant	
aspergillosis	by	Mavridou	et	al.37	This	study	showed	that	posacon-
azole	retains	activity	against	an	A. fumigatus	strain	that	carried	the	
TR34/L98H	mutation	with	a	posaconazole	MIC	of	0.5	mg/L	as	long	
as	 serum	 drug	 levels	 are	 sufficiently	 high.	No	 human	 data	 on	 the	
use	of	this	treatment	strategy	have	been	published.	However,	 in	a	
phase	3	pharmacokinetics	and	safety	study	for	posaconazole	tablets	
the	 average	 serum	 concentration	of	 posaconazole	 in	 quartile	 4	 of	
the	186	patients	that	received	posaconazole	tablets	at	300	mg	per	
day	was	2.3-	9.5	mg/L.	 It	was	not	associated	with	a	 specific	 safety	
signal	and	therefore,	a	serum	level	between	3	and	4	mg/L	is	a	realis-
tic	target.38	Posaconazole	with	high	serum	trough	levels	is	the	only	
oral	 step-	down	 treatment	 option	 for	 patients	with	 azole-	resistant	
IA.	Although	clinical	evidence	remains	anecdotal,	preclinical	animal	
studies	 and	 experience	 in	 veterinary	 medicine	 provides	 proof	 op	
principle	in	its	efficacy.37,39
5  | CONCLUSION
This	survey	shows	the	heterogeneous	landscape	in	the	prevention,	
diagnosis	and	treatment	of	IA	in	The	Netherlands.	In	the	context	of	
the	rapidly	increasing	prevalence	of	azole-resistance,	the	AzorMan	
study	was	implemented	to	evaluate	a	uniform	diagnostic	and	thera-
peutic	approach.
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